Interleukin-15 in gene therapy of cancer

Autores
Ochoa, Maria C.; Mazzolini Rizzo, Guillermo Daniel; Hervas Stubbs, Sandra; Sanmamed, Miguel Fernandez de; Berraondo, Pedro; Melero, Ignacio
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Interleukin-15 (IL-15) exerts powerful stimulatory effects on lymphocyte subsets that result in antiviral and antitumoral activities. The functions of this cytokine are mainly mediated in a cell-to-cell contact fashion termed IL-15 trans-presentation. This function is mediated by a cell which tethers IL-15 to its plasmatic membrane complexed to IL-15 receptor alpha (IL-15Rá). Such surface complexes interact with interleukin-2 receptor beta and gamma on the adjacent cell to elicit signaling. Unlike interleukin-2, IL-15 protects from activation-induced cell death and does not promote regulatory cells. These features underlie its activity against transplanted tumors and its adjuvanticity in tumor and viral vaccines. The GMP-manufactured recombinant protein is undergoing clinical trials but its rapid renal clearance calls for biotechnological strategies to increase molecular weight and ensure IL-15Rá. trans-presentation. Since early efforts with stable transfected tumor cells, IL-15 has been tested in a variety gene therapy approaches. Those mainly include transfer of expression cassettes to tumor cells, T cells, dendritic cells, vaccination sites and the liver as a biofactory organ. Detailed mechanistic knowledge of IL-15 biology is envisaged to make the most of a powerful immunotherapeutic tool ranked as one of the most promising for cancer immunotherapy.
Fil: Ochoa, Maria C.. Universidad de Navarra; España
Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Hervas Stubbs, Sandra. Universidad de Navarra; España
Fil: Sanmamed, Miguel Fernandez de. Universidad de Navarra; España
Fil: Berraondo, Pedro. Universidad de Navarra; España
Fil: Melero, Ignacio. Universidad de Navarra; España
Materia
Interleukin 15
Gene Therapy
Cancer
Immunotherapy
Cytokine
Interleukin 2
Tumors
T Cells
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/22627
Acceder
id CONICETDig_a29367f994a59cc2a24adc68a9c7a8d2
oai_identifier_str oai:ri.conicet.gov.ar:11336/22627
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Interleukin-15 in gene therapy of cancerOchoa, Maria C.Mazzolini Rizzo, Guillermo DanielHervas Stubbs, SandraSanmamed, Miguel Fernandez deBerraondo, PedroMelero, IgnacioInterleukin 15Gene TherapyCancerImmunotherapyCytokineInterleukin 2TumorsT Cellshttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Interleukin-15 (IL-15) exerts powerful stimulatory effects on lymphocyte subsets that result in antiviral and antitumoral activities. The functions of this cytokine are mainly mediated in a cell-to-cell contact fashion termed IL-15 trans-presentation. This function is mediated by a cell which tethers IL-15 to its plasmatic membrane complexed to IL-15 receptor alpha (IL-15Rá). Such surface complexes interact with interleukin-2 receptor beta and gamma on the adjacent cell to elicit signaling. Unlike interleukin-2, IL-15 protects from activation-induced cell death and does not promote regulatory cells. These features underlie its activity against transplanted tumors and its adjuvanticity in tumor and viral vaccines. The GMP-manufactured recombinant protein is undergoing clinical trials but its rapid renal clearance calls for biotechnological strategies to increase molecular weight and ensure IL-15Rá. trans-presentation. Since early efforts with stable transfected tumor cells, IL-15 has been tested in a variety gene therapy approaches. Those mainly include transfer of expression cassettes to tumor cells, T cells, dendritic cells, vaccination sites and the liver as a biofactory organ. Detailed mechanistic knowledge of IL-15 biology is envisaged to make the most of a powerful immunotherapeutic tool ranked as one of the most promising for cancer immunotherapy.Fil: Ochoa, Maria C.. Universidad de Navarra; EspañaFil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Hervas Stubbs, Sandra. Universidad de Navarra; EspañaFil: Sanmamed, Miguel Fernandez de. Universidad de Navarra; EspañaFil: Berraondo, Pedro. Universidad de Navarra; EspañaFil: Melero, Ignacio. Universidad de Navarra; EspañaBentham Science Publishers2013-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/22627Ochoa, Maria C.; Mazzolini Rizzo, Guillermo Daniel; Hervas Stubbs, Sandra; Sanmamed, Miguel Fernandez de; Berraondo, Pedro; et al.; Interleukin-15 in gene therapy of cancer; Bentham Science Publishers; Current Gene Therapy; 13; 1; 2-2013; 15-301566-52321875-5631CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/105901/articleinfo:eu-repo/semantics/altIdentifier/doi/10.2174/1566523211313010003info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:21:53Zoai:ri.conicet.gov.ar:11336/22627instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:21:53.337CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Interleukin-15 in gene therapy of cancer
title Interleukin-15 in gene therapy of cancer
spellingShingle Interleukin-15 in gene therapy of cancer
Ochoa, Maria C.
Interleukin 15
Gene Therapy
Cancer
Immunotherapy
Cytokine
Interleukin 2
Tumors
T Cells
title_short Interleukin-15 in gene therapy of cancer
title_full Interleukin-15 in gene therapy of cancer
title_fullStr Interleukin-15 in gene therapy of cancer
title_full_unstemmed Interleukin-15 in gene therapy of cancer
title_sort Interleukin-15 in gene therapy of cancer
dc.creator.none.fl_str_mv Ochoa, Maria C.
Mazzolini Rizzo, Guillermo Daniel
Hervas Stubbs, Sandra
Sanmamed, Miguel Fernandez de
Berraondo, Pedro
Melero, Ignacio
author Ochoa, Maria C.
author_facet Ochoa, Maria C.
Mazzolini Rizzo, Guillermo Daniel
Hervas Stubbs, Sandra
Sanmamed, Miguel Fernandez de
Berraondo, Pedro
Melero, Ignacio
author_role author
author2 Mazzolini Rizzo, Guillermo Daniel
Hervas Stubbs, Sandra
Sanmamed, Miguel Fernandez de
Berraondo, Pedro
Melero, Ignacio
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Interleukin 15
Gene Therapy
Cancer
Immunotherapy
Cytokine
Interleukin 2
Tumors
T Cells
topic Interleukin 15
Gene Therapy
Cancer
Immunotherapy
Cytokine
Interleukin 2
Tumors
T Cells
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Interleukin-15 (IL-15) exerts powerful stimulatory effects on lymphocyte subsets that result in antiviral and antitumoral activities. The functions of this cytokine are mainly mediated in a cell-to-cell contact fashion termed IL-15 trans-presentation. This function is mediated by a cell which tethers IL-15 to its plasmatic membrane complexed to IL-15 receptor alpha (IL-15Rá). Such surface complexes interact with interleukin-2 receptor beta and gamma on the adjacent cell to elicit signaling. Unlike interleukin-2, IL-15 protects from activation-induced cell death and does not promote regulatory cells. These features underlie its activity against transplanted tumors and its adjuvanticity in tumor and viral vaccines. The GMP-manufactured recombinant protein is undergoing clinical trials but its rapid renal clearance calls for biotechnological strategies to increase molecular weight and ensure IL-15Rá. trans-presentation. Since early efforts with stable transfected tumor cells, IL-15 has been tested in a variety gene therapy approaches. Those mainly include transfer of expression cassettes to tumor cells, T cells, dendritic cells, vaccination sites and the liver as a biofactory organ. Detailed mechanistic knowledge of IL-15 biology is envisaged to make the most of a powerful immunotherapeutic tool ranked as one of the most promising for cancer immunotherapy.
Fil: Ochoa, Maria C.. Universidad de Navarra; España
Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Hervas Stubbs, Sandra. Universidad de Navarra; España
Fil: Sanmamed, Miguel Fernandez de. Universidad de Navarra; España
Fil: Berraondo, Pedro. Universidad de Navarra; España
Fil: Melero, Ignacio. Universidad de Navarra; España
description Interleukin-15 (IL-15) exerts powerful stimulatory effects on lymphocyte subsets that result in antiviral and antitumoral activities. The functions of this cytokine are mainly mediated in a cell-to-cell contact fashion termed IL-15 trans-presentation. This function is mediated by a cell which tethers IL-15 to its plasmatic membrane complexed to IL-15 receptor alpha (IL-15Rá). Such surface complexes interact with interleukin-2 receptor beta and gamma on the adjacent cell to elicit signaling. Unlike interleukin-2, IL-15 protects from activation-induced cell death and does not promote regulatory cells. These features underlie its activity against transplanted tumors and its adjuvanticity in tumor and viral vaccines. The GMP-manufactured recombinant protein is undergoing clinical trials but its rapid renal clearance calls for biotechnological strategies to increase molecular weight and ensure IL-15Rá. trans-presentation. Since early efforts with stable transfected tumor cells, IL-15 has been tested in a variety gene therapy approaches. Those mainly include transfer of expression cassettes to tumor cells, T cells, dendritic cells, vaccination sites and the liver as a biofactory organ. Detailed mechanistic knowledge of IL-15 biology is envisaged to make the most of a powerful immunotherapeutic tool ranked as one of the most promising for cancer immunotherapy.
publishDate 2013
dc.date.none.fl_str_mv 2013-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/22627
Ochoa, Maria C.; Mazzolini Rizzo, Guillermo Daniel; Hervas Stubbs, Sandra; Sanmamed, Miguel Fernandez de; Berraondo, Pedro; et al.; Interleukin-15 in gene therapy of cancer; Bentham Science Publishers; Current Gene Therapy; 13; 1; 2-2013; 15-30
1566-5232
1875-5631
CONICET Digital
CONICET
url http://hdl.handle.net/11336/22627
identifier_str_mv Ochoa, Maria C.; Mazzolini Rizzo, Guillermo Daniel; Hervas Stubbs, Sandra; Sanmamed, Miguel Fernandez de; Berraondo, Pedro; et al.; Interleukin-15 in gene therapy of cancer; Bentham Science Publishers; Current Gene Therapy; 13; 1; 2-2013; 15-30
1566-5232
1875-5631
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/105901/article
info:eu-repo/semantics/altIdentifier/doi/10.2174/1566523211313010003
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Bentham Science Publishers
publisher.none.fl_str_mv Bentham Science Publishers
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781728355516416
score 12.982451

Publicaciones similares